Indian diagnostics-wellness, speciality and non-metros to drive FY27 growth

Rating agency ICRA’s latest update on the Indian diagnostic industry projects that organised players will grow revenue 12 to 14 percent in FY2027, a step up from the 10 to 12 percent CAGR the broader industry has been tracking through FY24–28 in earlier assessments. The upgrade reflects a structural shift in what diagnostic chains sell, and where: away from a commoditised, single-test business fighting on price in large cities, and toward curated wellness packages, specialised and chronic-disease testing, and geographic expansion into tier-2, tier-3 and tier-4 markets that remain significantly under-penetrated.

Wellness and speciality testing change the revenue mix
The clearest driver of the upgrade is the growing share of wellness and preventive-health revenue in diagnostic chains’ books. Industry data compiled by rating agencies shows wellness and preventive-care revenue has grown at more than 25 percent CAGR over the four years to FY25 for a sample of large chains, taking its share of total revenue from roughly 6 to 12 percent in FY21 to 12 to 25 percent in FY25. Diagnostic companies have increasingly bundled tests into curated packages tailored by age, gender and risk profile, allowing them to capture higher realisation per patient even as pricing for standalone tests stays under pressure. Specialised and chronic-disease-linked testing is following a similar trajectory, becoming a steadier, higher-margin complement to routine pathology work.

Beyond metros: Where the volume is
The other pillar of the growth story is geography. Despite more than 60 per cent of India’s population living outside large cities, urban markets still account for over 70 percent of diagnostic industry revenue. Established players have been opening collection centres and satellite labs across tier-2, tier-3 and even tier-4 towns, betting that rising incomes, growing health awareness and the spread of insurance coverage will lift both test volumes and, over time, willingness to pay for higher-value wellness and speciality packages in these markets. ICRA and other rating agencies expect this non-metro push, more than any recovery in metro pricing, to be the main volume engine behind FY2027 growth.

What listed players are already signalling
Company-level guidance and recent quarters bear out the trend. Dr Lal PathLabs has guided for FY27 revenue growth of 13 to 15 percent, with EBITDA margins held steady in the 27 to 28 percent range, helped by an expanding non-Covid, wellness-led testing mix and a deeper push into smaller towns. Metropolis Healthcare closed a recent quarter with revenue growth near 23 percent year-on-year, while Vijaya Diagnostics and Thyrocare have both reported record or near-record revenues. Brokerages tracking the sector have flagged hospitals and diagnostics as among the steadiest corporate earnings stories heading into the April to June 2026 quarter, with double-digit growth extending a run that has now lasted several quarters.

Pricing power stays limited
The one caveat running through the ratings commentary is that growth remains overwhelmingly a volumes story rather than a pricing one. The core testing market remains fragmented and highly competitive, and organised chains have limited ability to raise prices on standalone tests without losing share to smaller local labs and aggregators. That keeps the onus on wellness bundling, speciality testing and operational efficiency to protect margins even as revenue grows. Rating agencies expect this competitive intensity to persist through FY27, meaning the sector’s growth will keep coming from doing more tests, and higher-value tests, rather than charging more for the same one.

Outlook
If the 12 to 14 percent growth projection holds, FY27 would mark one of the strongest years yet for organised diagnostic chains, reinforcing a multi-year shift in the industry’s centre of gravity from routine, metro-centric pathology testing toward wellness, speciality and non-metro-led volumes. The key swing factors to watch will be how quickly non-metro centres reach profitable scale, whether wellness packages can keep growing as a share of revenue without diluting realisation, and whether competitive intensity in core testing stays contained enough for organised players to hold on to the margins they have built over the past few years.
MB Bureau